Related Experiment Video
Updated: Aug 31, 2026

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
A case of prolonged cefiderocol therapy during continuous hemodiafiltration in a patient with an implanted left
Hiroshi Kimura1,2, Takaaki Yano1,2, Yukiro Kurokawa1,2
1Division of Pharmacy, Ehime University Hospital, Toon, Ehime, Japan.
Abstract:
Cefiderocol (CFDC) is a siderophore cephalosporin with activity against multidrug-resistant Gram-negative pathogens, and it is considered a treatment option for refractory Gram-negative infections. Because CFDC is primarily eliminated by the kidneys, dose individualization is required in patients with renal impairment and in those receiving renal replacement therapy. During continuous hemodiafiltration (CHDF), drug clearance is influenced not only by residual renal function but also by dialysis and filtration flow rates and membrane characteristics; thus, careful determination of dose and dosing interval is necessary. However, real-world evidence on CFDC dosing during CHDF, particularly for prolonged courses, remains limited. We report a case of refractory Pseudomonas aeruginosa bacteremia in a patient with an implanted left ventricular assist device receiving CHDF, successfully managed with a 55-day course of CFDC using a dosing strategy tailored to CHDF settings.
Related Concept Videos
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Continuous Renal Replacement Therapy
Hemodialysis I: Introduction
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Hemodialysis II: Procedure and Complications
Peritoneal Dialysis I: Introduction and Procedure